IRS(Irradiation Stent) vs. CS(Conventional Stent) Insertion in Inoperable Malignant Biliary Obstruction
IRCSMBO
Study of Stent Insertion Combined With or Without Brachytherapy in Patients With Inoperable Malignant Biliary Obstruction
1 other identifier
interventional
328
1 country
1
Brief Summary
Stenting the malignant biliary obstruction is considered to be the preferred palliation modality to relieve pruritus,cholangitis,pain and jaundice in patients without surgical indications of malignant biliary obstruction.An unicentral clinical trial has demonstrated the safety and technical feasibility of an irradiation biliary stent insertion in patients with biliary obstruction caused by adenocarcinomas, such a treatment seems have benefits in relieving jaundice and extending survival when compared to a conventional biliary stent.However,the small sample size,the population distribution of two groups will influence the final results in obtaining a powerful statistical conclusion.Therefore,a multicentric study was designed to prospectively compared the responses to the treatment with this irradiation biliary stent versus the conventional biliary self-expandable stent in patients with inoperable malignant biliary obstruction.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Oct 2013
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2013
CompletedFirst Submitted
Initial submission to the registry
November 22, 2013
CompletedFirst Posted
Study publicly available on registry
December 5, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2016
CompletedFebruary 14, 2017
February 1, 2017
2.9 years
November 22, 2013
February 12, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Patency
Time from stenting to the day when stricture/obstruction of the stent occured or restricture/reobstruction after recanalization the obstructed stent.
Participants will be followed till die or lost to follow-up,an expected average of a year.
Secondary Outcomes (3)
Over survival
Participants will be followed till die or lost to follow-up,an expected average of a year.
Clinical success
Participants will be followed till die or lost to follow-up,an expected average of a year.
Safety
Participants will be followed till die or lost to follow-up,an expected average of a year.
Study Arms (2)
Biliary SEMS loaded with 125I seeds
EXPERIMENTALA self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
Conventional biliary SEMS
ACTIVE COMPARATORA self-expandable metallic biliary stent is inserted in patients with inoperable malignant biliary obstruction.
Interventions
A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
Eligibility Criteria
You may qualify if:
- Clinical,histological or pathological diagnosis of malignant biliary obstruction
- Unresectability or refusal to be surgically treated
- The Eastern Cooperative Oncology Group(ECOG) scores from 0 to 3
- With symptoms such as jaundice related to biliary obstruction
- Willing and able to comply with the study procedures and provide written informed consent to participate in the study
- Biliary obstruction of Bismuthe-Corlette,type I and II
You may not qualify if:
- Benign biliary obstruction
- The Eastern Cooperative Oncology Group(ECOG) score of 4
- Biliary tract stricture that could not be dilated enough to pass the delivery system
- Presence of metallic biliary stent or bile duct surgery
- Percutaneous transhepatic cholangiography(PTC) procedure was contraindicated
- Active hepatitis
- Biliary obstruction of Bismuthe-Corlette,type Ⅲ and Ⅳ
- Uncooperative or could not provide authorization and signature
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Zhongda Hospitallead
Study Sites (1)
Zhongda Hospital,Southeast University
Nanjing, Jiangsu, 210009, China
Related Publications (1)
Zhu HD, Guo JH, Huang M, Ji JS, Xu H, Lu J, Li HL, Wang WH, Li YL, Ni CF, Shi HB, Xiao EH, Lv WF, Sun JH, Xu K, Han GH, Du LA, Ren WX, Li MQ, Mao AW, Xiang H, Zhang KX, Min J, Zhu GY, Su C, Chen L, Teng GJ. Irradiation stents vs. conventional metal stents for unresectable malignant biliary obstruction: A multicenter trial. J Hepatol. 2018 May;68(5):970-977. doi: 10.1016/j.jhep.2017.12.028. Epub 2018 Jan 10.
PMID: 29331343DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Gao-jun Teng, Ph.D,MD
Zhongda Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Radiology & Chair,Department of Radiology
Study Record Dates
First Submitted
November 22, 2013
First Posted
December 5, 2013
Study Start
October 1, 2013
Primary Completion
September 1, 2016
Study Completion
September 1, 2016
Last Updated
February 14, 2017
Record last verified: 2017-02
Data Sharing
- IPD Sharing
- Will not share